12 recruiting. 12 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 12 |
| Phase 2 | 4 | Recruiting 4 |
Follow Bronchiolitis: new trials by email Literature Review of Bronchiolitis trials Research Report on Bronchiolitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graft-versus-Host Disease After Haploidentical Stem Cell Transplantation in Children 1mg /kg VIC-1911 - GVHD (Acute or Chronic) | Phase 1 | Recruiting | Shanghai Jiao Tong University School of Medicine | 9 | 2026-09-28 | 2026-10-20 |
| A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function. AHB-137 injection - Chronic Hepatitis B | Phase 1 | Recruiting | Ausper Biopharma Co., Ltd. | 32 | 2026-07-09 | 2026-07-29 |
| Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD EVE-Treg - Graft Versus Host Disease (cGvHD) | Phase 1 | Recruiting | Sarah Nikiforow, MD | 21 | 2026-05-29 | 2026-10-29 |
| Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD Belumosudil - Chronic Graft Versus Host Disease | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 8 | 2026-02-09 | 2026-08-27 |
| A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease Adrixetinib - Chronic Graft-Versus-Host Disease | Phase 1 | Recruiting | Qurient Co., Ltd. | 18 | 2025-12-23 | 2025-12-30 |
| Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD Fostamatinib, Ruxolitinib - Chronic Graft Versus Host Disease | Phase 1 | Recruiting | Stefanie Sarantopoulos, MD, PhD. | 30 | 2025-10-29 | 2026-01-22 |
| A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury OPC1 - Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic | Phase 1 | Recruiting | Lineage Cell Therapeutics, Inc. | 10 | 2025-06-30 | 2026-02-12 |
| Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy Gecacitinib Hydrochloride Tablets - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Recruiting | Yujun DONG | 24 | 2025-06-30 | 2025-06-10 |
| Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders Tafasitamab, Fludarabine phosphate, Cyclophosphamide - Autoimmune Disorders, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 47 | 2024-07-31 | 2026-10-06 |
| Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) TRX103 - Hematologic Malignancy, GvHD | Phase 1 | Recruiting | Tr1X, Inc. | 36 | 2024-04-08 | 2025-04-15 |
| Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies donor lymphocyte infusion, Cyclophosphamide, Busulfan - Hematologic Neoplasms | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 430 | 2022-05-23 | 2026-10-16 |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine - Hematologic Neoplasms | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 320 | 2021-09-23 | 2026-10-16 |
Bronchiolitis Obliterans Syndrome (12) · Graft vs Host Disease (4) · Hematologic Neoplasms (3) · Autoimmune Diseases (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Leukemia, Myelomonocytic, Chronic (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Myelodysplastic Syndromes (1) · Paralysis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Quadriplegia (1) · Scleroderma, Systemic (1)
Bronchial Diseases (12) · Bronchiolitis Obliterans (12) · Bronchitis (12) · Immune System Diseases (12) · Lung Diseases (12) · Lung Diseases, Obstructive (12) · Organizing Pneumonia (12) · Respiratory Tract Diseases (12) · Graft vs Host Disease (8) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Pathological Conditions, Signs and Symptoms (3)
Cyclophosphamide (3) · Mycophenolic Acid (2) · Sirolimus (2) · fludarabine (2) · Busulfan (1) · Filgrastim (1) · Mesna (1) · Whole-Body Irradiation (1) · belumosudil (1) · fludarabine phosphate (1) · fostamatinib (1) · ruxolitinib (1) · tafasitamab (1)
M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Ausper Biopharma Co., Ltd. (1) · Lineage Cell Therapeutics, Inc. (1) · Qurient Co., Ltd. (1) · Sarah Nikiforow, MD (1) · Shanghai Jiao Tong University School of Medicine (1) · Stefanie Sarantopoulos, MD, PhD. (1) · Tr1X, Inc. (1) · Yujun DONG (1)
United States (8) · China (3) · Spain (1)
Christopher G Kanakry, M.D. (2) · Amin Alousi, MD (1) · Chenyu Lin, MD (1) · Chitra Hosing, MD (1) · Jing Zhang (1) · Maria Grazia Roncarolo, MD (1) · Yuxian Huang (1)